Keyphrases
11C-acetate
25%
Acute Myocardial Infarction
53%
Adrenergic Blockers
10%
Angina
19%
Angiotensin-converting Enzyme Inhibitor (ACEi)
16%
Beta-blockers
16%
Captopril
20%
Carbon-11
31%
Cardiac Transplantation
21%
Cardiac Troponin
12%
Cardiomyopathy
12%
Chronic Coronary Artery Disease
11%
Confidence Interval
13%
Congestive Heart Failure
40%
Coronary Artery Disease
12%
Coronary Revascularization
10%
Coronary Vasospasm
10%
Exercise Training
10%
Fatty Acid Metabolism
10%
Fluorine-18 Fluorodeoxyglucose
11%
Functional Recovery
16%
H215O
17%
Heart Failure
14%
Hemodialysis Patients
10%
Infarct Size
48%
Infarction
68%
Inferior Infarction
17%
Left Ventricular Dysfunction
16%
Left Ventricular Ejection Fraction
10%
Left Ventricular Function
14%
Maximal Oxygen Uptake
11%
Metabolism
12%
Myocardial Infarction
90%
Myocardial Ischemia
14%
Myocardial Metabolism
24%
Myocardial Oxygen Consumption
22%
Myocardial Perfusion
34%
Myocardium
29%
Nifedipine
17%
Oxidative Metabolism
21%
Palmitate
36%
Patient Management
14%
Patients with Heart Failure
20%
Perfusion
21%
Positron Emission Tomography
88%
Positron Tomography
21%
Tissue Plasminogen Activator (t-PA)
10%
Transplantation
13%
Ventricular Enlargement
27%
Viable Myocardium
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acetic Acid C 11
23%
Acute Heart Infarction
38%
Adrenergic Receptor Blocking Agent
10%
Angina Pectoris
9%
Calcium Channel Blocker
7%
Captopril
21%
Carbon 11
59%
Cardiovascular Disease
6%
Clinical Study
6%
Combination Therapy
10%
Congestive Cardiomyopathy
10%
Congestive Heart Failure
73%
Coronary Artery Disease
21%
Coronary Artery Spasm
16%
Coronary Vasodilating Agent
7%
Creatine Kinase
8%
Diabetes Mellitus
6%
Dipeptidyl Carboxypeptidase Inhibitor
19%
Dipyridamole
10%
Fatty Acid
12%
Fibrinolytic Agent
11%
Fluorine 18
15%
Fluorodeoxyglucose
12%
Fluorodeoxyglucose F 18
8%
Functional Status
5%
Galectin 3
5%
Glyceryl Trinitrate
6%
Heart Infarction
100%
Heart Left Ventricle Failure
18%
Heart Muscle Injury
7%
Heart Muscle Ischemia
12%
Hypertension
8%
Infarction
92%
Left Ventricular Systolic Dysfunction
8%
Mibefradil
5%
Mortality Rate
6%
Myocardial Disease
13%
Nifedipine
17%
Nonischemic Cardiomyopathy
5%
Normal Human
29%
Oxygen 15
14%
Palmitic Acid
30%
Placebo
15%
Streptokinase
5%
Systolic Heart Failure
5%
Thorax Pain
13%
Thrombocyte Factor 4
5%
Thrombosis
6%
Tracer
7%
Troponin I
9%
Medicine and Dentistry
ACE Inhibitor
20%
Acetic Acid
16%
Acetic Acid C 11
13%
Acute Heart Infarction
20%
Aerobic Metabolism
21%
Angina pectoris
18%
Angina Pectoris
8%
Blood Clot Lysis
10%
Captopril
8%
Carbon 11
36%
Cardiovascular System
7%
Clinical Trial
7%
Combination Therapy
10%
Congestive Heart Failure
68%
Coronary Artery
9%
Coronary Artery Disease
26%
Coronary Vasodilating Agent
7%
Coronary Vasospasm
10%
Deterioration
9%
Dipyridamole
11%
Diseases
7%
Exercise
11%
Fluorine-18
9%
Fluorodeoxyglucose
6%
Fluorodeoxyglucose F 18
9%
Glucose Metabolism
9%
Heart Graft
8%
Heart Muscle Blood Flow
7%
Heart Muscle Metabolism
12%
Heart Muscle Oxygen Consumption
12%
Heart Muscle Perfusion
35%
Heart Muscle Revascularization
9%
Heart Transplantation
23%
Hemodialysis
16%
Infarction
32%
Left Ventricular Systolic Dysfunction
9%
Myocardial Disease
9%
Myocardial Infarction
42%
Myocardium
24%
Nifedipine
16%
Oxygen 15
8%
Oxygen Consumption
13%
Palmitic Acid
17%
Patient Care
7%
Placebo
7%
Positron Emission Tomography
63%
Revascularization
9%
Right Ventricle
9%
Transplantation
12%
Troponin I
7%